Macrogen begins construction of ‘Global Genome Center’ in Songdo, Incheon < AI/Medical Devices < Company < Text of Article

Macrogen (CEO Kim Chang-hoon) held a groundbreaking ceremony for ‘Songdo Global Genome Center’, Asia’s largest genome big data hub.

The groundbreaking ceremony was held at the Songdo High-Tech Industry Cluster on the morning of the 24th with the attendance of key figures including Macrogen Chairman Seo Jeong-sun, CEO Kim Chang-hoon, Incheon Free Economic Zone Authority Deputy Director Byun Ju-young, and General Manager Kim Jong-hwan. Macrogen plans to begin building a genome big data hub with the goal of completion in the second half of 2025.

Songdo Global Genome Center is a building with a total floor area of ​​5,700 pyeong, one underground floor and eight above-ground floors, and is located on a 6,017㎡ site in the Songdo High-Tech Industrial Cluster. Macrogen’s Gasan Genome Center located in Seoul will be expanded and relocated to the Songdo Global Genome Center in Incheon and will be operated in an integrated manner. In addition to the existing genome analysis facilities, a medical and healthcare linkage platform development center, integrated logistics management facility, and employee welfare space will be established to improve functionality and welfare. promotes

The center will function as a global genomic big data hub that accelerates the digital transformation of healthcare by combining big data, including genomic information, and artificial intelligence (AI). In addition, it serves as a ‘genome foundry’ that vertically integrates the value chain of the genome business to streamline and speed up the entire process, while maximizing competitiveness by dramatically increasing production capacity (CAPA) and reducing costs through automation in the global market beyond the domestic market. Aiming.

Kim Chang-hoon, CEO of Macrogen, said, “The start of construction of the Songdo Global Genome Center will be a stepping stone for Macrogen to leap forward as a world-class digital healthcare company. We will contribute to the realization of personalized precision medicine through the convergence of genomic big data and AI technology, and provide global “We will maximize our competitiveness in the market,” he said.